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Abstract 
A 42-year-old Hispanic female was referred for investigation of unexplained weight loss. 
Initial upper endoscopy showed atrophic gastritis. Repeat endoscopy one year later 
revealed the presence of mixed composite tumor consisting of gastric adenocarcinoma 
and carcinoid tumors. Treatment was accomplished by surgical excision. Such cases are 
extremely rare and few such reports are available in the literature. We discuss the 
pathologies and means by which these tumors are classified and treated. 
Introduction 
Gastric cancer remains one of the leading causes of cancer-related deaths worldwide. 
The incidence of gastric neoplasm varies greatly throughout the world and calls into 
question the role of ethnicity, dietary and environmental impact on tumorigenesis [1]. 
Nearly 90% of gastric tumors are malignant, of which 95% are due to adenocarcinoma [1]. 
Gastric carcinoids, once considered a rare contributor to the aggregate group of 
gastrointestinal tumors, have been increasing in prevalence during recent years [2, 3]. It 
has been hypothesized that this increase in prevalence is owed to improved pathological 
methods for detection and a more aggressive approach to screening [4]. We present the 
case of an asymptomatic 42-year-old female who underwent routine upper endoscopy for 
anemia. Repeat endoscopy one year later revealed the presence of a composite tumor 
consisting of gastric adenocarcinoma and carcinoid tumors.  
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Gastric Carcinoids 
Carcinoid tumors are growths whose cellular components are derived from 
neuroendocrine cells. These tumors may or may not be in association with the carcinoid 
syndrome, depending on their production of active hormones, most notably the 
monoamine 5-hydroxytryptamine (5-HT or serotonin). There have been cases where 
carcinoid syndrome was found to be associated with the release of substrates such as 
epinephrine, norepinephrine, histamine, gastrin, adrenocorticotrophic hormone, 
melanocyte-stimulating hormone, calcitonin, vasoactive intestinal peptide, glucagon and 
somatostatin [5, 6]. Occasionally, immunohistologic analysis reveals the secretion of 
multiple hormones [6]. Carcinoid activity can be monitored by measurement of urinary 
5-hydroxyindoleacetic acid, a byproduct of serotonin metabolism. Carcinoids can be 
subclassified based on the hormones produced, however the main determinants are 
cytoarchitectural components and specific immunohistochemical staining properties [5]. 
The appearance of carcinoid syndrome is dependent on the location of the tumor and 
occurs in locations where the venous drainage bypasses the liver’s catabolic activities. 
Unfortunately, many gastric carcinoids are diagnosed rather late due to the absence of 
carcinoid syndrome [3, 5]. Carcinoid tumors have been reported to occur in various 
organs throughout the body, with the most common locations being the jejunum, ileum, 
as well as the appendix and lungs. Carcinoids remain the most common primary 
neoplasm of the appendix. Although slow to progress, carcinoids may form metastatic 
lesions which are generally larger than their primary tumors, with a predilection for the 
mesenteric lymph nodes, liver and lung [6]. 
Gastric Adenocarcinoma 
Adenocarcinoma is the most common type of histologic malignancy of gastric tissue. 
On occasion, gastric adenocarcinoma has been reported to coexist with other types of 
histologic malignancies found in the gastrointestinal tract, such as gastrointestinal 
stromal tumors, mucosal-associated lymphoid tissue and carcinoid tumors among others 
[7]. Concurrent existence of gastric adenocarcinoma with chronic atrophic gastritis is a 
well-documented entity [8]. Similarly, there has been documented evidence of increased 
occurrence of both gastric adenocarcinoma and gastric carcinoid tumors in patients with 
underlying pernicious anemia [1, 3, 8, 9]. This is possibly due to metaplastic changes 
associated with chronic mucosal inflammation leading to the deposition of glandular 
cells. It is suggested that in patients with decreased acid secretion and thus increased 
gastrin levels, gastrin may serve as a trophic hormone by inducing hyperplasia of the 
neuroendocrine cells and inciting the formation of carcinoid tumor cells [10, 11]. The 
treatment for gastric adenocarcinoma is surgery with either adjuvant or neoadjuvant 
therapy. 
Case Report 
We present the case of a 42-year-old female referred after experiencing a 6-pound weight loss the 
month prior. There was no nausea, vomiting, diarrhea, bloody stools or menorrhagia. The patient has a 
10-year history of pernicious anemia treated with intramuscular vitamin B12 injections. She is currently 
under treatment for Hashimoto’s hypothyroidism and has a long history of chronic constipation. There 
was no history of alcohol, tobacco or drug use. She had a positive family history of colon carcinoma  
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from her father. Physical examination was unremarkable. Laboratory examination from the referring 
physician unavailable. 
She was evaluated with upper endoscopy for identification of the cause for her iron deficiency 
anemia. Endoscopy revealed a 1.5–2.0 cm polyp along the greater curvature of the distal body of the 
stomach (fig. 1). Biopsy demonstrated intestinal metaplasia with patchy epithelial atypia, indefinite for 
dysplasia and mild chronic gastritis, however without evidence of adenocarcinoma. It was suggested 
that the gastritis be treated medically and a repeat biopsy be performed if clinical suspicion of neoplasm 
remained. Unfortunately the patient decided to delay her follow-up evaluation for one year.  
One year after initial endoscopic biopsy the patient returned, experiencing intermittent episodes 
of flushing and abdominal bloating. Laboratory examination identified resolution of the anemia with 
hemoglobin of 13.4 g/dl, hematocrit of 39.1%, and mean corpuscular volume of 94 fl. Endoscopic 
ultrasound was performed which demonstrated a gastric polypoid lesion emanating from the second 
mucosal layer with a superficial cystic structure noted within the submucosa (fig. 2). The muscularis 
propria was intact and no adenopathy was observed followed by endoscopic mucosal resection (fig. 3). 
The polyp from the body of the stomach measured 1.3 × 1.2 × 1.1 cm and displayed mixed 
adenocarcinoma and carcinoid with extension to the muscularis mucosae and submucosa. The 
specimen demonstrated antral type mucosa and intestinal metaplasia on a background of chronic 
gastritis. The specimen, indentified as an infiltrating epithelial neoplasm, demonstrated two 
morphologically separate components. One portion contained mucinous glands with clusters of cells 
displaying moderate to marked nuclear atypia most suggestive of intestinal adenocarcinoma. 
Intertwined with these mucinous glands were small clusters of cells with far less atypical nuclei with 
marked neuroendocrine appearance representing a focus of carcinoid tumor (fig. 4). The carcinoid 
portion of the tumor was relatively small and extended into the submucosa. Staining was positive for 
chromogranin A and synaptophysin and keratins: 40, 48, 50, 52, 54, 56.5, 58, 59, 64, 67 (fig. 5). The 
thiazine differential and immunoperoxidase stains were negative for Helicobacter pylori. MRI of the 
abdomen done with and without contrast showed no evidence of metastatic disease. Definitive 
treatment was accomplished by partial gastrectomy as the patient is doing well and approaching her 
two-year follow-up without evidence of disease or return of symptoms.  
Discussion 
Studies have found an association between gastric carcinoid tumors and autoimmune 
atrophic gastritis with hypergastrinemia [8]. It has been suggested that H. pylori, on a 
foundation of atrophic gastritis, may also be a contributing factor in the development of 
gastric carcinoid tumors [12]. Carcinoids have been identified in gastric tissue in 
association with hypergastrinemia-related syndromes, namely multiple endocrine 
neoplasia type 1 (Wermer syndrome) and Zollinger-Ellison syndrome as well as in 
patients without hypergastinemia [6, 8, 12, 13]. It is suggested that effects of prolonged 
hypergastremic states predispose the mucosal cells to hyperplasia, especially in the setting 
of atrophic gastritis [13]. While carcinoids are generally more indolent in nature, they 
may demonstrate a greater degree of malignant potential if in occurrence with 
concomitant gastric adenocarcinoma [14]. According to Rindi et al., gastric carcinoid 
tumors can be classified into three distinct subtypes. Type I includes carcinoids that 
develop on a foundation of atrophic corporal gastritis, type II includes carcinoids 
associated with MEN type I syndrome or Zollinger-Ellison syndrome, and type III 
includes carcinoids with malignant features in the absence of hypergastrinemia [15], with 
type III being the mostly likely to undergo regional lymph node metastasis and therefore 
accompanied by the worst prognosis [8]. In our case the patient falls into type I, as 
evidenced by the background of atrophic gastritis seen on endoscopic and pathologic 
examination with subsequent MRI demonstrating no evidence for regional lymph node 
metastasis. Rindi’s classification correlated with different survival rates in the three  
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subgroups, with group I having the best overall prognosis in that series. Based on this, the 
treatment of isolated carcinoid tumors should proceed based on the subtype identified. 
Many gastric adenocarcinomas have neuroendocrine components. Likewise, 
neuroendocrine tumors have demonstrated areas composed of adenocarcinomatous cells. 
These combinations have been described as ‘composite’ or mixed glandular-endocrine 
tumors [16]. At present, it is unclear whether the two cell types are due to proliferation of 
two distinct cell lines or rather a proliferation of a single line of pluripotent cellular 
precursor cells that divide into the two cells types [16]. 
Lewin [6] classifies the group of tumors demonstrating mixed epithelial and endocrine 
components into three subgroups. Group I consists of composite glandular-endocrine cell 
tumors, group II of amphicrine tumors and group III of collision tumors. Lewin classifies 
collision tumors as a subtype in which a carcinoid abuts an adjacent adenocarcinoma or 
adenoma with the two distinct cell types in juxtaposition to one another without evidence 
of intermixing. The group I classification allows for mixed cellular components without a 
fixed neuroendocrine to endocrine ratio [6]. In our case, the patients’ pathology is most 
consistent with Lewin’s group I classification. The reason for such differentiation 
accounts for the tumor’s distinctive clinical behavior at particular anatomic locations and 
may serve as a guide to directing treatment. In our case, management was directed 
towards the larger and generally more aggressive adenocarcinoma component. 
Conclusion 
Atrophic gastritis as well as pernicious anemia have been found to be risk factors for 
the development of both gastric adenocarcinoma and carcinoid tumors [13]. In such 
patients, surveillance by endoscopic means can be employed to offset the increased risk 
of neoplastic development. Recently there is a trend to follow such patients with type I 
gastric carcinoids with surveillance endoscopy and to avoid surgical management. The 
study by Gladdy et al. [8] demonstrated no appreciable difference in mortality between 
patients followed by endoscopy when compared with surgical intervention. However, in 
patients with concurrent gastric adenocarcinoma, surgical resection is generally preferred. 
In this particular patient, management proceeded with surgical resection, however in 
cases where the tumor does not display submucosal invasion, endoscopic mucosal 
resection may serve as a definitive treatment. The decision to proceed with surgical 
resection was justified as the patient has no evidence of disease after one year of 
follow-up. As in our case, management should generally be directed towards the more 
aggressive and threatening component of the neoplasm to assure the best outcome. 
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Fig. 1. Upper endoscopy showing a polypoid mass in the body of the stomach. 
 
 
 
Fig. 2. Endoscopic ultrasound demonstrating the polypoid lesion with extension through the 
submucosal layer.  
 
 
 
Fig. 3. Repeat endoscopy with resection of the polyp in the body of the stomach. 
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Fig. 4. Hematoxylin and eosin staining of the polyp demonstrating glandular tissue (adenocarcinoma) 
(black arrow) and foci of endocrine cells (carcinoid) (red arrow). 
 
 
 
Fig. 5. Immunoperoxidase stain with positivity for synaptophysin (red arrow) in carcinoid and 
negativity in adenocarcinoma (black arrow). 
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